Advances on chronic obstructive pulmonary disease associated pulmonary hypertension

doi:10.3969/j.issn.1674-490X.2022.03.004

Abstract

Abstract: Chronic obstructive pulmonary disease(COPD)has become a global public health problem due to its large number of patients, high mortality rate and heavy social and economic burden. Pulmonary hypertension, pulmonary heart disease and heart failure caused by COPD seriously threaten life health and quality of life of patients. The quality of life can be improved if the disease can be controlled in time, effectively controlled and slowed down. This article reviews the pathogenesis, clinical manifestations, diagnosis and treatment of COPD associated pulmonary hypertension.

Key words: chronic obstructive pulmonary disease, pulmonary hypertension, pathogenesis, diagnosis, treatment

CLC Number:

WANG Jing, HAN Li, ZHANG Zeming. Advances on chronic obstructive pulmonary disease associated pulmonary hypertension[J]. Journal of Hebei Medical College for Continuing Education, 2022, 39(3): 21-28.

References

[1] Global initiative for chronic obstructive lung disease.Global strategy for the diagnosis, management, andprevention of chronic obstructive pulmonary disease(2020 REPORT)[EB/OL].(2019-12-20)[2021-08-06]. https://goldcopd.org/gold-reports/.
[2] Global initiative for chronic obstructive lung disease.Global strategy for the diagnosis, management, andprevention of chronic obstructive pulmonary disease(2021 REPORT)[EB/OL].(2020-11-18)[2021-08-06]. https://goldcopd.org/gold-reports/.
[3] OSWALD-MAMMOSSER M, APPRILL M, BACHEZ P, et al. Pulmonary hemodynamics in chronic obstructive pulmonary disease of the emphysematous type[J]. Respiration, 1991, 58(5/6): 304-310. DOI: 10.1159/000195950.
[4] THABUT G, DAURIAT G, STERN J B, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation[J]. Chest, 2005, 127(5): 1531-1536. DOI: 10.1378/chest.127.5.1531.
[5] SCHARF S M, IQBAL M, KELLER C, et al. Hemodynamic characterization of patients with severe emphysema[J]. Am J Respir Crit Care Med, 2002, 166(3): 314-322. DOI: 10.1164/rccm.2107027.
[6] TSENG S, STANZIOLA A A, SULTAN S, et al. Pulmonaryhypertension related to chronic obstructive pulmonary disease and diffuse parenchymal lung disease:afocus on right ventricular(dys)function[J]. Heart Fail Clin, 2018, 14(3): 403-411. DOI: 10.1016/j.hfc.2018.03.006.
[7] 中华医学会呼吸病学分会肺栓塞与肺血管病学组,中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会,全国肺栓塞与肺血管病防治协作组, 等. 中国肺动脉高压诊断与治疗指南(2021版)[J].中华医学杂志, 2021, 101(1): 11-51. DOI: 10.3760/cma.j.cn112137-20201008-02778.
[8] ACKER S N, SEEDORF G J, ABMAN S H, et al. Pulmonary artery endothelial cell dysfunction and decreased populations of highly proliferative endothelial cells in experimental congenital diaphragmatic hernia[J]. Am J Physiol Lung Cell Mol Physiol, 2013, 305(12): L943-L952. DOI: 10.1152/ajplung.00226.2013.
[9] PISARCIK S, MAYLOR J, LU W J, et al. Activation of hypoxia-inducible factor-1 in pulmonary arterial smooth muscle cells by endothelin-1[J]. Am J Physiol Lung Cell Mol Physiol, 2013, 304(8): L549-L561. DOI: 10.1152/ajplung.00081.2012.
[10] CHESTER A H, YACOUB M H. The role of endothelin-1 in pulmonary arterial hypertension[J]. Glob Cardiol Sci Pract, 2014, 2014(2): 62-78. DOI: 10.5339/gcsp.2014.29.
[11] LI J, CAO Y X, LIU H, et al. Enhanced G-protein coupled receptors-mediated contraction and reduced endothelium-dependent relaxation in hypertension[J]. Eur J Pharmacol, 2007, 557(2/3): 186-194. DOI: 10.1016/j.ejphar.2006.11.057.
[12] MORRIS T A. Why acute pulmonary embolism becomes chronic thromboembolic pulmonary hypertension: clinical and genetic insights[J]. Curr Opin Pulm Med, 2013, 19(5): 422-429. DOI: 10.1097/MCP.0b013e328364379f.
[13] RITCHIE A I, WEDZICHA J A. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations[J]. Clin Chest Med, 2020, 41(3): 421-438. DOI: 10.1016/j.ccm.2020.06.007.
[14] 张俊志,李涵葳,张中军,等.TNF-α在先天性体-肺分流性肺动脉高压大鼠中的表达变化[J].华中科技大学学报(医学版), 2018, 47(4): 445-449. DOI: 10.3870/j.issn.1672-0741.2018.04.012.
[15] ZAKYNTHINOS E, DANIIL Z, PAPANIKOLAOU J, et al. Pulmonary hypertension in COPD: pathophysiology and therapeutic targets[J]. Curr Drug Targets, 2011, 12(4): 501-513. DOI: 10.2174/138945011794751483.
[16] BORRONI R, DI BLASIO A M, GAFFURI B, et al. Expression of GnRH receptor gene in human ectopic endometrial cells and inhibition of their proliferation by leuprolide acetate[J]. Mol Cell Endocrinol, 2000, 159(1/2): 37-43. DOI: 10.1016/s0303-7207(99)00199-9.
[17] 魏剑琴,李青山,辛秀芹.慢性阻塞性肺疾病病人白三烯代谢与呼吸功能改变的关系研究[J].吉林医学, 2005, 26(10): 1128. DOI: 10.3969/j.issn.1004-0412.2005.10.059.
[18] 李立宇,王辰,庞宝森,等.慢性阻塞性肺疾病急性期凝血纤溶系统功能变化的临床研究[J]. 中国实用内科杂志, 2008, 28(8): 667-669.
[19] 夏文娟,王学中,梅晓冬. D-二聚体和C反应蛋白在慢性阻塞性肺病进展中的变化及对肺动脉高压严重程度的预测作用[J].临床检验杂志, 2018, 36(9): 687-690. DOI: 10.13602/j.cnki.jcls.2018.09.11.
[20] DAURIAT G, REYNAUD-GAUBERT M, COTTIN V, et al. Severe pulmonary hypertension associated with chronic obstructive pulmonary disease:a prospective french multicenter cohort[J].J Heart Lung Transplant, 2021, 40(9): 1009-1018. DOI: 10.1016/j.healun.2021.04.021.
[21] NAKAYAMA S, CHUBACHI S, SAKURAI K, et al. Characteristics of chronic obstructive pulmonary disease patients with pulmonary hypertension assessed by echocardiography in a three-year observational cohort study[J].Int J Chron Obstruct Pulmon Dis, 2020, 15: 487-499. DOI: 10.2147/COPD.S230952.
[22] 王若溪,王同生,苏秀丽,等.慢性阻塞性肺疾病合并肺动脉高压患者的随访观察[J].中华结核和呼吸杂志, 2021, 44(8): 717-722. DOI: 10.3760/cma.j.cn112147-20201013-01038.
[23] ROBERTS J D, FORFIA P R. Diagnosis and assessment of pulmonary vascular disease by Doppler echocardiography[J]. Pulm Circ, 2011, 1(2): 160-181. DOI: 10.4103/2045-8932.83446.
[24] 范玉春,郭晓酮,孙潇,等.心脏磁共振成像对慢性阻塞性肺疾病合并肺动脉高压患者肺动脉血流动力学及右心功能的临床评价[J].中华危重病急救医学, 2019, 31(8): 972-977. DOI: 10.3760/cma.j.issn.2095-4352.2019.08.012.
[25] SWIFT A J, RAJARAM S, CONDLIFFE R, et al. Pulmonary artery relative area change detects mild elevations in pulmonary vascular resistance and predicts adverse outcome in pulmonary hypertension[J]. Invest Radiol, 2012, 47(10): 571-577. DOI: 10.1097/RLI.0b013e31826c4341.
[26] AGOSTON-COLDEA L, LUPU S, MOCAN T. Pulmonary artery stiffness by cardiac magnetic resonance imaging predicts major adverse cardiovascular events in patients with chronic obstructive pulmonary disease[J]. Sci Rep, 2018, 8(1): 14447. DOI: 10.1038/s41598-018-32784-6.
[27] JOHNS C S, RAJARAM S, CAPENER D A, et al. Non-invasive methods for estimating mPAP in COPD using cardiovascular magnetic resonance imaging[J]. Eur Radiol, 2018, 28(4): 1438-1448. DOI: 10.1007/s00330-017-5143-y.
[28] RAHAGHI F N, VAN BEEK E J R, WASHKO G R. Cardiopulmonary coupling in chronic obstructive pulmonary disease: the role of imaging[J]. J Thorac Imaging, 2014, 29(2): 80-91. DOI: 10.1097/RTI.0000000000000076.
[29] NISTAL M A S. Pulmonary hypertension: the contribution of MDCT to the diagnosis of its different types[J]. Radiologia, 2010, 52(6): 500-512. DOI: 10.1016/j.rx.2010.05.012.
[30] IYER A S, WELLS J M, VISHIN S, et al. CT scan-measured pulmonary artery to aorta ratio and echocardiography for detecting pulmonary hypertension in severe COPD[J]. Chest, 2014, 145(4): 824-832. DOI: 10.1378/chest.13-1422.
[31] TRUONG Q A, MASSARO J M, ROGERS I S, et al. Reference values for normal pulmonary artery dimensions by noncontrast cardiac computed tomography: the framingham heart study[J]. Circ Cardiovasc Imaging, 2012, 5(1): 147-154. DOI: 10.1161/CIRCIMAGING.111.968610.
[32] MINIATI M, MONTI S, AIRÒ E, et al. Accuracy of chest radiography in predicting pulmonary hypertension: a case-control study[J]. Thromb Res, 2014, 133(3): 345-351. DOI: 10.1016/j.thromres.2013.12.019.
[33] COSTE F, BENLALA I, DOURNES G, et al. Assessing pulmonary hypertension in COPD. Is there a role for computed tomography? [J]. Int J Chronic Obstr Pulm Dis, 2019, 14: 2065-2079. DOI: 10.2147/copd.s207363.
[34] RICH J D, THENAPPAN T, FREED B,et al. QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension[J]. Int J Cardiol, 2013, 167(3):669-676. DOI: 10.1016/j.ijcard.2012.03.071.
[35] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2021年修订版)[J].中华结核和呼吸杂志, 2021, 44(3): 170-205. DOI: 10.3760/cma.j.cn112147-20210109-00031.
[36] RIETEMA H, HOLVERDA S, BOGAARD H J, et al. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity[J]. Eur Respir J, 2008, 31(4): 759-764. DOI: 10.1183/09031936.00114207.
[37] RUBIN L J, BADESCH D B, FLEMING T R, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study[J]. Chest, 2011, 140(5): 1274-1283. DOI: 10.1378/chest.l0-0969.
[38] XIONG C M, LU X L, SHAN G L, et al. Oral sildenafil therapy for Chinese patients with pulmonary arterial hypertension: a multicenter study[J]. J Clin Pharmacol, 2012, 52(3):425-431. DOI: 10.1177/0091270011398241.
[39] GHOFRANI H A, STAEHLER G, GRÜNIG E, et al. Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease[J]. Pulm Circ, 2015, 5(2): 296-304. DOI: 10.1086/680214.
[40] PICHL A, SOMMER N, BEDNORZ M, et al. Riociguat for treatment of pulmonary hypertension in COPD: a translational study[J]. Eur Respir J, 2019, 53(6): 1802445. DOI: 10.1183/13993003.02445-2018.
[41] SUN Y J, XIONG C M, SHAN G L, et al. Inhaled low-dose iloprost for pulmonary hypertension: a prospective, multicenter, open-label study[J]. Clin Cardiol, 2012, 35(6): 365-370. DOI: 10.1002/clc.21987.
[42] BARNES P J. Future treatments for chronic obstructive pulmonary disease and its comorbidities[J]. Proc Am Thorac Soc, 2008, 5(8): 857-864. DOI: 10.1513/pats.200807-069TH.
[43] LU Y B, CHANG R X, YAO J, et al. Effectiveness of long-term using statins in COPD:a network meta-analysis[J]. Respir Res, 2019, 20: 17. DOI: 10.1186/s12931-019-0984-3.
[44] WANG G Z, SHANG W L, REN Y J, et al. Benefits of statins in chronic obstructive pulmonary disease patients with pulmonary hypertension: a meta-analysis[J].Eur J Intern Med, 2019, 70: 39-42. DOI: 10.1016/j.ejim.2019.09.009.